Dushen Chetty is the Global Head of Oncology Development at Novartis, where he oversees the entire oncology portfolio and leads the Oncology Development Leadership Team. He manages a team of "asset CEOs"and is a member of the Novartis Development Leadership Team. Previously, Dushen spearheaded prostate cancer development at Novartis Oncology, focusing on pioneering PSMA-targeted Radioligand Therapies. His leadership has contributed to regulatory approvals for Pediatric Glioma and BRaf Tumor Agnostic indications. Before joining Novartis, Dushen served as Senior Director at Janssen Oncology, designing innovative strategies for hK2-targeting radio-conjugates in prostate cancer, bladder cancer drug delivery devices, and oncolytic virus programs. During his 15 years at GlaxoSmithKline, he led scientific licensing teams, shaped oncology business development strategies, and established an R&D unit in Singapore through partnerships with local institutes and government bodies. Dushen holds a PhD from Rutgers University as a Fulbright Scholar and was a British Council Scholar at King's College London. As an Associate Professor in South Africa, he founded a drug delivery research program. His career reflects a commitment to advancing oncology innovation globally.